Explore the Agenda
8:20 am Check In & Morning Coffee
9:20 am Chair’s Opening Remarks
Envisioning the Success of Peptide-Based Therapeutics Enabled by Robust Biopharma Partnerships, Investments & Innovation Strategies
9:30 am Business Development & Investment Panel Discussion — Exploring the Future of Peptide-Therapeutics Through Successful Funding Rounds, Biopharmaceutical Partnerships & Collaborations
The biopharmaceutical sector continues to innovate peptide discovery innovations, from new macrocycles to new delivery methods and are thriving on strategic alliances, which allow for cross-functional sharing of knowledge, and experience to advance peptide drugs to patients faster. Hear first-hand how investors and key biotechs are keeping up with the peptide momentum through investments, alliances and collaborations.
Key questions to be addressed include:
- How to strategize the complexities, risks and decision-making strategies for choosing the right platform to invest and advance innovative approaches in the peptide industry?
- What are the key areas and spaces that peptides can fill in the biotechnology sector?
- What does it take for a small biotech to survive and get noticed from an investor or big pharma?
10:00 am The Peptide IP Landscape: Winning with Knowledge, Strategy & Innovation from Peptide Discovery to Development
- Harnessing critical understanding of regulatory and IP implications from drug discovery to formulation to ensure smooth market access for your peptide therapeutic
- Outlining the key IP bottlenecks for making changes to peptide drugs
- Defining the data packages required to be sufficient for IP submissions
10:30 am Morning Break & Networking
Track A: Drug Discovery
Trailblazing the Next Wave of Peptide Design Through Physics & De Novo Approaches Towards Next Generation Peptide Therapeutic Modalities
11:00 am From Traditional Peptide Discovery to Physics-Based AI Design – A Case Study of GLP-1 & β-Catenin Programs
- Showcasing a traditional drug discovery case study with example of GLP-1 class drugs highlighting the challenges with these approaches
- Demonstrating the application of AI/ML and physics-based tools to design novel peptide binders with drug-like properties, enabling multi-objective optimization toward a potential clinical candidate
- Presenting a case of current β-catenin project using physics-based AI approaches
11:30 am Discovery & Characterization of a Selective, Pure Antagonist of TNFR1
- Introducing de novo designed miniproteins as a next generation therapeutic modality
- Highlighting the application to antagonism of TNFR1
- Showcasing differentiation against existing therapies
Track B: Formulation & CMC
Harnessing Carrier Systems & Peptides as Drug Delivery Vehicles to Enable Laser- Focused Targeting of Peptide Drug Delivery
11:00 am Unlocking a Peptide-Based Platform for Targeted Delivery of Therapeutic Agents
- Rationally designing and optimizing AI-driven peptide-vectors for targeted delivery of different payloads including peptide, protein and RNA
- Demonstrating safety and characterization of peptide-based nanoparticles for extrahepatic delivery of RNA
- Leveraging a peptide-based nanoparticle platform for systemic targeted delivery of therapeutic mRNA: T cell engineering and tumor selectivity
NEW COMPANY
11:30 am Revolutionizing Intracellular Delivery with an Advanced Peptide-Based Platform for Clinical Success
- Pioneering endosomal escape through rationally designed peptide shuttles, enabling efficient delivery of small molecules, proteins, enzymes and oligonucleotides across diverse cell types
- Delivering functional biomolecules in different animal models
- Demonstrating clinical potential of the Feldan technology through in vivo data and progression to first-in-human trial for basal cell carcinoma
NEW COMPANY
12:00 pm Lunch Break & Networking
Track A: Drug Discovery
Leveraging Case Study Examples of Peptide Discoveries to Achieving High Potency & Selectivity of Peptide-Based Therapeutics & Vaccines
1:00 pm Non-Degradative Macrocyclic Molecular Glue DELs
- RapaGlues are non-degrading molecular glues that recruit FKBP12 to form a new PPI ternary complex, successfully
- addressing the large portion of the undrugged cytosolic and transmembrane proteome
- Leveraging the RapaGlue Platform’s proprietary DELs (over 8 billion compounds) and AI/ML-powered predictions for modelling-guided design to explore the topological diversity required to expand the range of targets
- RapaGlues promote the intracellular assembly of a proteinsized (+12kD) inhibitor, achieving a high success rate against multiple hard-to-drug targets with high potency, selectivity, and cell permeability
NEW DATA
1:30 pm Active Immunotherapy Using Universal Epitopes
- Peptide vaccine technology involves prolonged suppression due to the production of anti-endogenous target protein antibody
- Peptide vaccines consist of highly immunogenic helper T cell epitope (AJP001) and B cell epitope originated from target protein
- Sharing the usefulness of antibody-inducing peptides based on non-clinical and clinical trial data of developed compounds
NEW COMPANY
Track B: Formulation & CMC
Overcoming Bioanalytical & CMC Challenges in Analyzing & Effectively Scaling Peptides to Meet Clinical & Regulatory Expectations
1:00 pm Developing a Fit for Purpose Bioanalytical Strategy to Analyze a Cell-Penetrating Peptide: From Protein Precipitation to Solid Phase Extraction to Affinity Capture
- Introducing the properties of cell penetrating peptides
- Discussing the challenges of bioanalysis
- Utilizing a fit for purpose bioanalytical strategy: from protein precipitation to solid phase extraction to affinity capture
1:30 pm Using the XeriSol Formulation Platform for Peptide Parenteral Drug Delivery
- Presenting a non-aqueous, high concentration subcutaneous solution
- Enabling room temperature stability
- Showcasing excellent safety and toxicity profiles
NEW COMPANY
2:00 pm Afternoon Break & Networking
Unravelling the Challenges to Effectively Design & Formulate Cell Penetrable Peptide Therapies with Effective Pharmacology, Kinetics & Dynamics to Improve Patient Outcomes
2:30 pm Roundtable Discussion: From Discovery to Translation; Developing Cell Permeable & Orally Bioavailable Peptides with Optimal Pharmacology & DMPK
- Modifying amino acids to optimise target selectivity and cell membrane permeability to achieve the right pharmacology
- Modelling protein-protein interactions in the discovery to translate into the preclinical setting
- Analysing the pharmacokinetic and biodistribution properties of highly soluble orally bioavailable peptides to ensure efficacy when entering the clinic
3:15 pm Peptide Inhibitor of Pan Corona Virus Fusion Protein
- Introducing of the Pan-Cov peptide inhibitor program and showcasing the peptide modality strategy
- Establishing in vitro and ex vivo efficacy assays for peptide optimization
- Discussing the challenges associated with peptide PK and biodistribution
NEW DATA